Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

TSHA vs MPLT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TSHA Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–1 Matrix Metrics)

TSHA Overall Winner 6-Pillar Tally: TSHA 4 – 0 MPLT (2 Tie) Matrix Metrics: TSHA 6 – 1 MPLT

As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TSHA carries a Unified Composite Score of 49.8/100 (HOLD) at $3.72 (N/M Forward P/E, -2998.0% operating margin), whereas MPLT carries 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: TSHA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TSHA vs MPLT
TSHA NASDAQ Head-to-Head Winner
Taysha Gene Therapies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.72
-1.33% 1D
Market Cap $1.2B
TTM Revenue $5.5M
Forward P/E N/M
Beta / 30D Vol 1.81β · 52% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 25.0 Fund 51.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 35
RSI-14: 34.7 · SMA20: $4.12 · SMA50: $4.35
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$5.94
-7.48% 1D
Market Cap $356.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 33.0 Fund 64.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.4%), weak momentum, RSI 30
RSI-14: 30.2 · SMA20: $7.08 · SMA50: $8.63

6-Pillar Scorecard Institutional Category Breakdown (TSHA 4 – 0 MPLT)

Columns: Metric · TSHA · MPLT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TSHA
Revenue Growth (YoY) +171.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.5M N/A
Market Cap $1.2B $356.8M
3. Profitability & Quality TSHA
Gross Margin 100.0% N/A
Operating Margin -2998.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -54.2% -74.2%
4. Balance Sheet & Cash Flow TSHA
Cash Generation (TTM) -$136M -$179M
Cash Flow Margin N/A N/A
Net Cash / Leverage $399M Net Cash $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TSHA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 300.8% (34th %ile) 97.5% (9th %ile)
Put/Call OI Skew 0.46x (Call-Skewed) 1.67x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TSHA (6) vs MPLT (1)
Institutional Metric TSHA MPLT Criterion Row Edge
Market Capitalization
Scale
$1.2B $356.8M Larger Scale TSHA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+171.3% +0.0% Higher Growth TSHA
Operating Margin (TTM)
Profitability
-2998.0% 0.0% Higher Margin MPLT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-54.2% -74.2% Higher ROE TSHA
52-Week Range Position
Momentum
7% ($3–$7) 0% ($6–$40) Stronger Trend TSHA
Beta / 30D Volatility
Risk Regime
1.81β · 52% Vol 1.19β · 79% Vol Lower Realized Risk TSHA
Unified Institutional Score
Composite Signal
49.8 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite TSHA
Trailing 12M Revenue (USD)
Operating Scale
$5.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$136M ($399M Net Cash) -$179M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TSHA +20.88 pp
TSHA: -7.12% · MPLT: -28.0%
3M Horizon TSHA +10.02 pp
TSHA: -37.69% · MPLT: -47.71%
6M Horizon TSHA +47.1 pp
TSHA: -32.24% · MPLT: -79.34%
1Y Horizon TSHA +52.09 pp
TSHA: -7.23% · MPLT: -59.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TSHA vs MPLT. Trailing 12-month operating profitability (TSHA -2998.0% vs MPLT 0.0%) and valuation multiples (TSHA N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TSHA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.5M
Gross Margin100.0%
Op. Margin-2998.0%
ROE / Fwd P/E-54.2% · N/M
MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TSHA BREAKDOWN
138d in phase · OBV DISTRIBUTION
Current IV 300.8%
IV Percentile 34th %ile
Put/Call OI Skew 0.46x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TSHA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 97.5%
IV Percentile 9th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TSHA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -2998.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $356.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TSHA vs MPLT Key Questions & Quantitative Answers

As of Nov 20, 2026, Taysha Gene Therapies, Inc. (TSHA) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TSHA carries a Unified Composite Score of 49.8/100 (HOLD) at $3.72 (N/M Forward P/E, -2998.0% operating margin), whereas MPLT carries 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: TSHA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TSHA leads the Growth & Scale pillar: TSHA posts +171.3% YoY revenue growth and +0.0% YoY earnings growth on $5.5M TTM revenue (100.0% gross margin, -2998.0% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TSHA generates $5.5M in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, TSHA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.

TSHA and MPLT trade at balanced relative valuation multiples. TSHA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TSHA (-54.2% ROE) versus MPLT (-74.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TSHA carries 300.8% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.46x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 52% Vol realized risk). By comparison, MPLT carries 97.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.